CCND2 and breast cancer: For MPB, the highest (vs. lowest) tertile was associated with a nonstatistically significant increase in the odds of hypomethylated CCND2 promoter‐defined BC (OR = 1.31, 95% CI = 0.93–1.84; CLR = 1.98) versus controls, and with a nonstatistically significant decrease in the odds of hypermethylated CCND2 promoter‐defined BC (OR = 0.71, 95% CI = 0.40–1.25; CLR = 3.13).